This math transform tool runs Price Natural Logarithm transformation and companion studies for Assembly Biosciences. The focus on price transformations that reveal shifts in trend structure helps organize trend, volatility, and risk context for Assembly Biosciences.
This analysis covers sixty-one data points across the selected time horizon. Assembly Biosciences Price Natural Logarithm is logarithm with base 'e' where e is equal to 2.718281828. It is applied on the entire Assembly Biosciences pricing series.
Assembly Biosciences Technical Analysis Modules
Most technical analysis of Assembly Biosciences help investors determine whether a current trend will continue and, if not, when it will shift. We provide a combination of tools to recognize potential entry and exit points for Assembly from various momentum indicators to cycle indicators. When you analyze Assembly charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.
Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus infection in the United States. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California. Assembly Biosciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 70 people. Market structure and macro sensitivity help explain how Assembly Biosciences behaves across regimes. Market sensitivity remains generally comparable to wider market conditions. Assembly Biosciences has a market cap of 444.7 M, ROE of -36.94%.
Methodology
Unless otherwise specified, financial data for Assembly Biosciences is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. Assembly (USA Stocks:ASMB) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions. Assumptions: Inputs are aggregated from public filings and market reference sources and public institutions such as U.S. Securities and Exchange Commission (SEC) via EDGAR and the U.S. Patent & Trademark Office (USPTO). Certain values may not reflect real-time changes. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.
Analyst Sources
Assembly Biosciences has active sell-side coverage. Source-validated coverage currently shows 4 approved analysts, while broader market-consensus totals may differ across providers due to methodology and update timing. 2 analysts have submitted revenue and/or earnings estimates that may be incorporated into Macroaxis consensus inputs where available. Representative analyst firms may include Morgan Stanley, RBC Capital Markets, Wells Fargo Securities, BMO Capital Markets, Stifel, among others. Updates may occur throughout the day.
Performance tracking around Assembly Biosciences should go beyond the latest gain or loss and focus on how the position changes overall portfolio efficiency over time. A disciplined tracking process turns performance data into better decisions instead of more noise.
Generate Optimal Portfolios
Align your risk and return expectations
Risk tolerance and time horizon inputs allow Macroaxis optimization to estimate acceptable risk levels. The output provides a structured risk context for return targets.
Understanding Assembly Biosciences typically begins with financial statements and long-term trend review. Key ratios help frame profitability, efficiency, and growth context for Assembly Biosciences Stock. Outlined below are key reports that provide context for Assembly Biosciences Stock:
Assembly Biosciences has a market cap of 444.7 M, operating margin of -100.87%, ROE of -36.94%. Review Trending Equities for broader portfolio context. The allocation includes a position in Assembly Biosciences within the portfolio mix. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
Before investing in Assembly Stock, review our How to Buy Assembly Biosciences guide for key considerations.Assembly Biosciences currently shows ROE of -36.94%, market cap of 444.7 Million. Investors get more value from Assembly Biosciences analysis when it is combined with the construction and diversification tools listed below. A thorough Assembly Biosciences review pairs this page with the quantitative and comparative resources listed below. You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Earnings Share
-4.60
Revenue Per Share
4.319
Quarterly Revenue Growth
0.576
Return On Assets
-0.16
Return On Equity
-0.37
The market value of Assembly Biosciences is measured differently than book value, which reflects Assembly accounting equity. Assembly Biosciences' market capitalization is 444.7 M. Assembly Biosciences P/B of 2.44 shows the market assigns a modest premium over accounting equity. Enterprise value stands at 216.72 M. Intrinsic value represents an estimate of underlying worth and can differ from both market price and book value. Valuation methods compare these perspectives to frame context.
Value and price for Assembly Biosciences are related but not identical, and they can diverge across cycles. For Assembly Biosciences, key inputs include a P/B ratio of 2.44, a profit margin of -103.65%, ROE of -36.94%, and revenue of 28.52 M. Where Assembly Biosciences trades at any moment depends on the balance of buying and selling pressure.